1 results match your criteria: "University of Nottingham and Scancell Ltd.[Affiliation]"
A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis.
Cancer Res
June 2006
Institute of Infections, Immunity, and Inflammation, Cancer Research UK Department of Clinical Oncology, University of Nottingham and Scancell Ltd., BioCity, Nottingham, United Kingdom.
Article Synopsis
- A novel monoclonal antibody was developed by immunizing mice with colorectal tumor cell lines and was found to bind specifically to a cell surface antigen prevalent in most colorectal tumors.
- The antibody, SC104, targets a specific sialyltetraosylceramide antigen, selectively expressed on various tumors, including esophageal and gastric cancers, with minimal presence in normal tissues.
- Notably, SC104 induces tumor cell death through a classic apoptotic pathway independently of immune cells, highlighting its potential for therapeutic use alongside other treatments like chemotherapy.